MA31677B1 - Potentiation d'une chimiotherapie anticancereuse par la 7-(2,5-dihydro-4-imidazo [1,2-a]pyrin-3-yl-2,5-dioxo-1h-pyrrol-3-yl) -9-fluoro-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)-pyrrolo[3,2,1-jk][1,4]benzodiazepine - Google Patents

Potentiation d'une chimiotherapie anticancereuse par la 7-(2,5-dihydro-4-imidazo [1,2-a]pyrin-3-yl-2,5-dioxo-1h-pyrrol-3-yl) -9-fluoro-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)-pyrrolo[3,2,1-jk][1,4]benzodiazepine

Info

Publication number
MA31677B1
MA31677B1 MA32562A MA32562A MA31677B1 MA 31677 B1 MA31677 B1 MA 31677B1 MA 32562 A MA32562 A MA 32562A MA 32562 A MA32562 A MA 32562A MA 31677 B1 MA31677 B1 MA 31677B1
Authority
MA
Morocco
Prior art keywords
perolo
carbonil
benzodiazepine
pyrrol
imidazo
Prior art date
Application number
MA32562A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Aktham Aburub
Marcio Chedid
Thomas Albert Engler
Venkatraghavan Vasudevan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39737054&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31677(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA31677B1 publication Critical patent/MA31677B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
MA32562A 2007-07-02 2010-01-27 Potentiation d'une chimiotherapie anticancereuse par la 7-(2,5-dihydro-4-imidazo [1,2-a]pyrin-3-yl-2,5-dioxo-1h-pyrrol-3-yl) -9-fluoro-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)-pyrrolo[3,2,1-jk][1,4]benzodiazepine MA31677B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94751207P 2007-07-02 2007-07-02
PCT/US2008/067614 WO2009006043A2 (en) 2007-07-02 2008-06-20 Potentiation of cancer chemotherapy by 7-(2,5-dihydro-4-imidazo [1,2-a]pyrine-3-yl-2,5-dioxo-ih-pyrrol-3-yl)-9-fluoro-1,2,3,4 tetrahydro-2-(1-piperidinyl-carbonyd-pyrrolo[3,2,1-jk][1,4]benzodiazepine

Publications (1)

Publication Number Publication Date
MA31677B1 true MA31677B1 (fr) 2010-09-01

Family

ID=39737054

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32562A MA31677B1 (fr) 2007-07-02 2010-01-27 Potentiation d'une chimiotherapie anticancereuse par la 7-(2,5-dihydro-4-imidazo [1,2-a]pyrin-3-yl-2,5-dioxo-1h-pyrrol-3-yl) -9-fluoro-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)-pyrrolo[3,2,1-jk][1,4]benzodiazepine

Country Status (22)

Country Link
US (2) US8318713B2 (enExample)
EP (1) EP2173348B1 (enExample)
JP (2) JP5551589B2 (enExample)
KR (1) KR101230085B1 (enExample)
CN (2) CN102772416A (enExample)
AR (1) AR067112A1 (enExample)
AU (1) AU2008270732B2 (enExample)
BR (1) BRPI0813789A2 (enExample)
CA (1) CA2691587C (enExample)
CL (2) CL2008001848A1 (enExample)
EA (2) EA023697B1 (enExample)
ES (1) ES2561202T3 (enExample)
IL (2) IL202237A (enExample)
MA (1) MA31677B1 (enExample)
MX (1) MX2009013449A (enExample)
MY (1) MY154472A (enExample)
NZ (1) NZ581355A (enExample)
PE (1) PE20090838A1 (enExample)
TW (1) TWI428132B (enExample)
UA (1) UA97400C2 (enExample)
WO (1) WO2009006043A2 (enExample)
ZA (1) ZA200908725B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI428132B (zh) * 2007-07-02 2014-03-01 Lilly Co Eli 癌症化療效果之強化
US8802668B2 (en) 2009-04-14 2014-08-12 Eli Lilly And Company Hematopoietic neoplasm chemotherapy
JP2014531456A (ja) * 2011-09-22 2014-11-27 バインド セラピューティックス インコーポレイテッド 治療用ナノ粒子と癌を治療する方法
WO2014050779A1 (ja) * 2012-09-25 2014-04-03 第一三共株式会社 Ｇｓｋ３阻害剤と抗ｄｒ５抗体の組み合わせ
CN107613983B (zh) * 2015-04-30 2021-05-04 大鹏药品工业株式会社 抗肿瘤剂的副作用减轻剂
US10213511B2 (en) * 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10016507B2 (en) * 2016-03-02 2018-07-10 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: III
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
CN110392686A (zh) * 2016-12-30 2019-10-29 频率治疗公司 1h-吡咯-2,5-二酮化合物以及使用它们来诱导干/祖支持细胞自我更新的方法
JP2022520671A (ja) 2019-02-08 2022-03-31 フリークエンシー・セラピューティクス・インコーポレイテッド 耳障害を治療するためのバルプロ酸化合物及びｗｎｔ作動薬
CA3222225A1 (en) * 2021-06-03 2022-12-08 University Of Cincinnati Bzd-1 as a chemosensitizer of cancer
CN113956157B (zh) * 2021-11-18 2024-05-03 西安都创医药科技有限公司 一种合成2-甲酰基-1-环丙烷甲酸乙酯的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8904161D0 (en) * 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
EP1788086A1 (en) * 1997-03-17 2007-05-23 Human Genome Sciences, Inc. Death Domain Containing Receptor 5
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
KR100974770B1 (ko) * 2002-03-05 2010-08-06 일라이 릴리 앤드 캄파니 키나제 억제제로서의 퓨린 유도체
CA2499639C (en) * 2002-09-19 2011-11-08 Schering Corporation Imidazopyridines as cyclin dependent kinase inhibitors
US20110293746A1 (en) * 2004-07-09 2011-12-01 Agency For Science, Technology And Research Modulation of Gsk-3Beta and Method of Treating Proliferative Disorders
GB0418328D0 (en) * 2004-08-17 2004-09-22 Imp College Innovations Ltd Cancer methods and medicaments
US20060252082A1 (en) * 2005-05-04 2006-11-09 University Of South Florida Predicting treatment response in cancer subjects
TWI428132B (zh) * 2007-07-02 2014-03-01 Lilly Co Eli 癌症化療效果之強化

Also Published As

Publication number Publication date
UA97400C2 (uk) 2012-02-10
US20130039996A1 (en) 2013-02-14
EP2173348A2 (en) 2010-04-14
CL2008001848A1 (es) 2009-05-29
US20100166884A1 (en) 2010-07-01
ES2561202T3 (es) 2016-02-25
CA2691587C (en) 2013-09-24
CN102772416A (zh) 2012-11-14
JP2010532364A (ja) 2010-10-07
IL218443A0 (en) 2012-04-30
AU2008270732A1 (en) 2009-01-08
US8648063B2 (en) 2014-02-11
EA201201155A1 (ru) 2014-11-28
KR101230085B1 (ko) 2013-02-05
BRPI0813789A2 (pt) 2014-12-30
ZA200908725B (en) 2011-02-23
JP5551589B2 (ja) 2014-07-16
PE20090838A1 (es) 2009-07-02
CA2691587A1 (en) 2009-01-08
EA023697B1 (ru) 2016-07-29
MY154472A (en) 2015-06-30
EA201070085A1 (ru) 2010-04-30
CL2011003046A1 (es) 2012-08-24
IL202237A (en) 2014-05-28
TW200911272A (en) 2009-03-16
CN101743005B (zh) 2013-06-12
KR20100017984A (ko) 2010-02-16
WO2009006043A2 (en) 2009-01-08
HK1141236A1 (zh) 2010-11-05
TWI428132B (zh) 2014-03-01
MX2009013449A (es) 2010-01-15
NZ581355A (en) 2012-04-27
US8318713B2 (en) 2012-11-27
CN101743005A (zh) 2010-06-16
AU2008270732B2 (en) 2013-01-31
WO2009006043A3 (en) 2009-04-16
IL202237A0 (en) 2010-06-16
AR067112A1 (es) 2009-09-30
EP2173348B1 (en) 2015-12-09
JP2014114297A (ja) 2014-06-26
EA018447B1 (ru) 2013-08-30

Similar Documents

Publication Publication Date Title
MA31677B1 (fr) Potentiation d'une chimiotherapie anticancereuse par la 7-(2,5-dihydro-4-imidazo [1,2-a]pyrin-3-yl-2,5-dioxo-1h-pyrrol-3-yl) -9-fluoro-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)-pyrrolo[3,2,1-jk][1,4]benzodiazepine
GEP20247679B (en) Bicyclic heterocycles as fgfr inhibitors
EA201270498A1 (ru) 8-этил-6-(арил)пиридо[2,3-d]пиримидин-7(8h)-оны для лечения заболеваний цнс
ATE517868T1 (de) Pyrazinverbindungen, ihre verwendung und herstellungsverfahren
MA49368B1 (fr) Imidazopyrimidines à substitution diazabicyclique et leur utilisation pour traiter des maladies des voies respiratoires
EA024630B9 (ru) Производные пиразола как ингибиторы ионных каналов, активируемых высвобождением кальция (crac)
MA47107B1 (fr) Dérivés de benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine et pyrido[2,3-d]pyrimidine en tant qu'inhibiteurs de kras g12c pour le traitement de cancer du poumon, du pancréas ou de l'intestin
NZ602362A (en) Imidazopyridines syk inhibitors
MA38146B1 (fr) Nouveaux dérivés du benzimidazole comme antagonistes ep4
PH12012501408A1 (en) Pyrazole derivatives as jak inhibitors
PH12013502369A1 (en) Diazacarbazoles and methods of use
MX2011012353A (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus.
MY150747A (en) Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
UA99597C2 (ru) Пиримидилциклопентаны как ингибиторы акт протеинкиназ
GEP20084552B (en) Tetrahydronaphthyridine derivatives useful as histamine h3 receptor ligands
MA37798B1 (fr) 4-méthyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphtalènes
WO2008086462A3 (en) AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS
MX2008011258A (es) Derivados de quinazolina como inhibidores de fosfodiesterasa 10.
MX349550B (es) 1,7-diazacarbazoles y metodos de uso.
WO2012171015A3 (en) Therapeutic combination for cancer treatment
EA201101180A1 (ru) Производные триазоло[4,3-в]пиридазина и их применение для рака предстательной железы
MX2009004771A (es) Compuestos heteroaril triciclicos utiles como inhibidores de janus cinasa.
MA34384B1 (fr) Composés hétérocycliques, leur préparation et leur application thérapeutique
MA33091B1 (fr) Combinaisons pharmaceutiques comprenant rdea119/bay 869766 pour le traitement de cancers specifiques
WO2022008627A3 (en) Improved method for the production of lysergic acid diethylamide (lsd) and novel derivatives thereof